|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1999-11-30 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1997-11-17 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1996-06-25 |
An Open-Label, Multiple Dose, Multicenter, Randomized, Two Sequence, Two-Treatment, fully Replicate, Cross-Over, Steady State, Bioequivalence Study of Test Product Leuprolide Acetate for Depot Suspension 7.5 mg of Pharmathen S.A. Greece with Reference Product Lupron Depot® 7.5 mg, Manufactured for AbbVie Inc. in Adult Male Patients with Prostate Carcinoma Undergoing Initial Therapy of Leuprolide Acetate. - NIL
An open label, multicenter, balanced, randomized, parallel, three-treatment, three arm, single-period, single dose comparative bioavailability study of Leuprolide acetate for depot suspension 30 mg for 4-month administration of Pharmathen S.A., Greece, with LUPRON DEPOT (Leuprolide Acetate for Depot Suspension) 30 mg for 4-month administration of AbbVie Inc. North Chicago, IL 60064 in adult male subjects with prostatic cancer undergoing initial therapy of leuprolide acetate 30 mg under fasting conditions. - 22-VIN-0466
A Randomized, Open Label, Multicenter, Two-treatment, Single-period, Multiple Dose, Parallel, Steady State Bioequivalence Study of Paliperidone Palmitate (3-month) Extended Release Injectable Suspension for intramuscular use 546 mg (350 mg Paliperidone) (Pharmathen S.A., Greece) compared to TREVICTA�® 350 mg Prolonged Release Suspension for injection (Janssen-Cilag International NV, Belgium) in adult schizophrenic patients.
100 项与 Pharmathen SA 相关的临床结果
0 项与 Pharmathen SA 相关的专利(医药)
100 项与 Pharmathen SA 相关的药物交易
100 项与 Pharmathen SA 相关的转化医学